The sickle cell disease as a Public Health problem in Brazil

Sickle cell anemia is the most prevalent hereditary disease in Brazil. However, the Brazilian literature registers no investigations into the public health aspects of the disease. This present study investigates the way of life of 80 adult patients (49 women and 31 men) with a diagnosis of sicklecell anemia, at a blood center in Brazil. The late diagnosis of the disease was one of the most significant aspects observed in this group of patients. It was also observed that the dominant problem faced by adult patients with sickle cell anemia is of an economic nature, mainly due to lack of professional opportunities. However, patients can well undertake economic activities under adequate medical supervision, according to their own limitations and potentialities. The psychoterapeutic orientation was well accepted by patients regardless of sex. It is concluded that there exists need for the establishment of community programs for early diagnosis and medical, social and psychological orientation for sickle cell anemia patients in Brazil.Apesar de a anemia falciforme ser a doença hereditária de maior prevalência no Brasil, a literatura nacional carece de investigações a respeito dos seus aspectos de Saúde Pública. Investigou-se a realidade vivida por 80 pacientes adultos (49 mulheres e 31 homens) com diagnóstico de anemia falciforme, seguidos regularmente em centro hematológico. O diagnóstico tardio da doença foi um dos principais aspectos detectados na casuística examinada. Observou-se que a problemática maior do paciente adulto com a anemia falciforme esta centrada nos aspectos econômicos, sobretudo na falta de oportunidades profissionais, apesar de os mesmos poderem participar do mercado de trabalho, desde que estejam recebendo tratamento médico adequado e exerçam funções compatíveis com as suas limitações e potencialidades. A orientação psicoterapêutica teve uma grande aceitação pelos pacientes, sem diferença significativa entre os sexos. Concluiu-se haver necessidade da implantação de programas comunitários de diagnóstico precoce e de orientação médica, social e psicológica dos doentes com a anemia falciforme no Brasil, bem como de aconselhamento genético não diretivo dos casais de heterozigotos com o traço falciforme

[turner Syndrome: Psychosocial Aspects].

Turner syndrome's (TS) incidence is about 1:2,130 live female births and its most important clinical features are short stature and gonadal dysgenesis, leading to primary amenorrhea, delayed pubertal development and infertility. Congenital and acquired anomalies and a great variety of dysmorphic signs can also be observed. Thus, many characteristics and symptoms may have bad consequences in the psychosocial aspects of the patients with TS. The objective of this paper is to review the literature on psychosocial aspects of TS, mainly the psychological effect caused by short stature, delayed pubertal development and infertility, self-esteem, social aspects, gender identity, sexual functioning, love relationships, family relationships, cognitive functioning, psychiatric diseases and the presence of a chronic disease. General remarks on psychological follow-up of the patients are also made.49157-6

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO